Chris Francis - 05 Feb 2026 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Role
SVP, Corporate Development, Head of Emerging Areas
Signature
/s/ Chris Francis
Issuer symbol
WVE
Transactions as of
05 Feb 2026
Net transactions value
-$25,326
Form type
4
Filing time
11 Feb 2026, 21:01:03 UTC
Previous filing
06 Jan 2026
Next filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Francis Chris SVP, Corporate Development, Head of Emerging Areas C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE /s/ Chris Francis 11 Feb 2026 0001657709

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WVE Ordinary Shares Award $0 +38,750 +155% $0.000000 63,750 05 Feb 2026 Direct F1
transaction WVE Ordinary Shares Sale $25,326 -1,883 -3% $13.45 61,867 09 Feb 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WVE Share Option (right to buy) Award $0 +232,500 $0.000000 232,500 05 Feb 2026 Ordinary Shares 232,500 $12.75 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
F2 On February 9, 2026, the reporting person sold 1,883 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
F3 The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.

Remarks:

SVP, Corporate Development, Head of Emerging Areas